CPBIO Holding Co (HKSE:03839) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03839 CPBIO Holding Co Ltd HKSE:03839
71 GF Score
Price HK$9.20
GF Value HK$4.36
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CPBIO Holding Co Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

CPBIO Holding Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HKSE:03839 vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CPBIO Holding Co Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where CPBIO Holding Co's Margin of Safety % (DCF Earnings Based) falls into.


HKSE:03839
71GF Score
CPBIO Holding Co Ltd HKSE:03839
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?

Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued. The current stock price of HK$9.20 is trading 110.9% above its estimated GF Value™ of HK$4.36. GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.

Key valuation signals for HKSE:03839:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: HK$4.36 vs. price of HK$9.20 (110.9% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CPBIO Holding Co Business Description

Address 16 Harcourt Road, 21st Floor, Far East Finance Centre, Central, Hong Kong, HKG
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score

Get the complete analysis for HKSE:03839

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$9.20
Price
HK$4.36
GF Value